SABCS 2021 | First-in-human results of CDK2/4/6 inhibition in breast and ovarian cancer
Timothy Yap, MBBS, PhD, FRCP, University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the results of a first-in-human Phase I/IIa dose-escalation/expansion study of the first-in-class CDK2/4/6 inhibtior PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer. In this study it was found that PF-3600 can be combined with endocrine therapy with a manageable safety profile and demonstrates promising preliminary antitumor activity in heavily pretreated patients. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.
Disclosures
Research support (to Institution): Repare, AstraZeneca, Artios, Bayer, Beigene, BioNTech, BMS, Clovis, Constellation, Cyteir , Eli Lilly, EMD Serono, Forbius, F-Star, Artios, GlaxoSmithKline, Genentech, Haihe, ImmuneSensor, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tesaro and Vivace
Consultancies: Repare, AstraZeneca, Almac, Aduro, Artios, Athena, Atrin, Axiom, Bayer, Bristol Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, GLG, Guidepoint, Ignyta, I-Mab, ImmuneSensor, Jansen, Merck, Pfizer, Roche, Schrodinger, Seattle Genetics, Varian, Zai Labs and ZielBio
